Alphina Therapeutics Strengthens Management Team With Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer
Alphina Therapeutics Strengthens Management Team With Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer
Deep expertise in oncology drug discovery and development positions Dr. Damelin to guide advancement of best-in-class NAMPT inhibitor program
Damelin 博士在腫瘤學藥物發現和開發方面的深厚專業知識使他能夠指導一流的 namPT 抑制劑計劃的推進
NEW HAVEN, Conn., Dec. 17, 2024 /PRNewswire/ -- Alphina Therapeutics, a biotechnology company developing a best-in-class NAMPT inhibitor for the treatment of a range of solid tumor indications, today announced that it has appointed Marc Damelin, Ph.D., as Chief Scientific Officer. Dr. Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of mechanisms of action. He has served in key scientific leadership roles at leading oncology-focused companies for more than 17 years and made important contributions to the discovery of multiple platform technologies and clinical compounds that resulted in several high-value partnerships.
康涅狄格州紐黑文,2024年12月17日 /PRNewswire/ — 開發用於治療一系列實體瘤適應症的一流NamPT抑制劑的生物技術公司Alphina Therapeutics今天宣佈,已任命馬克·達梅林博士爲首席科學官。達梅林博士在各種作用機制的腫瘤藥物發現和開發方面擁有豐富的行業經驗。他在專注於腫瘤學的領先公司擔任關鍵科學領導職務超過17年,並對多平台技術和臨牀化合物的發現做出了重要貢獻,從而建立了多個高價值的合作伙伴關係。
Alphina's approach to NAMPT inhibition leverages several novel insights and a synthetic lethality strategy to significantly increase the therapeutic index of its small molecules. Unlike other programs previously in the clinic against this target, the company has developed a proprietary patient selection assay to identify the significant percentage of patients with non-small cell lung, small cell lung, colorectal, ovarian, and other solid tumors which are substantially more likely to respond to its drug candidates. Alphina has also engineered and optimized its molecules to mitigate the toxicities associated with previous NAMPT inhibitors.
Alphina的namPT抑制方法利用了多種新見解和合成殺傷力策略來顯著提高其小分子的治療指數。與之前針對該目標開展的其他項目不同,該公司開發了一種專有的患者選擇測定方法,以識別很大比例的非小細胞肺、小細胞肺、結直腸、卵巢和其他實體瘤患者,這些患者對候選藥物產生反應的可能性要大得多。Alphina還設計和優化了其分子,以減輕與先前NamPT抑制劑相關的毒性。
"As we work toward advancing our lead NAMPT inhibitor program into the clinic, now is the perfect time to add someone with Marc's impressive scientific experience and drug development track record," said Nick Galli, Alphina's Chief Executive Officer. "We are thrilled to welcome Marc to the leadership team and will lean on his expertise to guide our NAMPT inhibitor program. At the same time, Marc's skill in drug discovery and development will prove valuable as we look to expand our portfolio by exploring new targets, programs, and modalities."
Alphina首席執行官尼克·加利說:「在我們努力將我們的領先namPT抑制劑項目推進到臨牀時,現在是增加具有Marc令人印象深刻的科學經驗和藥物研發記錄的人的最佳時機。」「我們很高興歡迎Marc加入領導團隊,並將依靠他的專業知識來指導我們的naMPT抑制劑計劃。同時,Marc在藥物發現和開發方面的技能將證明是有價值的,因爲我們希望通過探索新的靶點、計劃和模式來擴大我們的產品組合。」
Dr. Damelin most recently served as Vice President and Head of Biology at Mersana Therapeutics, a Cambridge, MA-based clinical-stage biopharmaceutical company focused on discovering and developing ADCs for cancers with high unmet medical need. During his tenure at Mersana, he played a key role in the discovery of novel ADC platform technologies and clinical-stage compounds, three of which have advanced into the clinic. His work was leveraged to create three partnerships that generated $170MM in upfront payments: an asset-based partnership with GSK and platform-based partnerships with Merck-Serono and Janssen (J&J). Prior to joining Mersana, Dr. Damelin spent a decade with Pfizer in the company's Oncology Research Unit, where he was the discovery project leader for multiple programs that advanced into the clinic and where he ultimately led the unit's ADC discovery efforts from target validation into clinical development.
達梅林博士最近在Mersana Therapeutics擔任副總裁兼生物學主管。Mersana Therapeutics是一家位於馬薩諸塞州劍橋的臨牀階段生物製藥公司,專注於發現和開發針對未滿足大量醫療需求的癌症的ADC。在Mersana任職期間,他在發現新的ADC平台技術和臨牀階段化合物的過程中發揮了關鍵作用,其中三種化合物已進入臨牀。利用他的工作建立了三個合作伙伴關係,產生了1.7億美元的預付款:與葛蘭素史克的基於資產的合作伙伴關係以及與默克雪蘭諾和詹森(J&J)的基於平台的合作伙伴關係。在加入 Mersana 之前,Damelin 博士在輝瑞公司的腫瘤學研究部門工作了十年,在那裏他是進入臨牀的多個項目的發現項目負責人,並最終領導了該部門從靶標驗證到臨牀開發的 ADC 發現工作。
"Having had the opportunity to work on cutting-edge approaches to oncology drug discovery and development for the past 17 years, it is clear to me that Alphina's data-driven, multi-pronged approach has great therapeutic potential," said Dr. Damelin. "Not only has the company created compounds with the potential to overcome the limitations of previous NAMPT inhibitor programs, but it has developed a proprietary patient selection assay to pair the drug candidate with those patients most likely to benefit from treatment. I look forward to working with the talented team at Alphina to create and execute a development plan that maximizes both the opportunity for success and the overall benefit to patients."
達梅林博士說:「在過去的17年中,我有機會研究前沿的腫瘤藥物發現和開發方法,我很清楚Alphina的數據驅動的多管齊下的方法具有巨大的治療潛力。」「該公司不僅創造了有可能克服先前NamPT抑制劑項目侷限性的化合物,而且還開發了一種專有的患者選擇試驗,將候選藥物與最有可能從治療中受益的患者配對。我期待與Alphina才華橫溢的團隊合作,制定和執行一項發展計劃,最大限度地提高成功機會和爲患者帶來整體利益。」
About Alphina Therapeutics
Alphina Therapeutics is a biotech company developing a best-in-class small molecule inhibitor of NAMPT to treat a variety of solid tumors. Founded by world-class scientists and backed by a strong investor syndicate of venture capitalists, the company is also developing a proprietary assay to enable selection of patients whose tumors harbor a specific perturbation which make their tumor exquisitely sensitive to Alphina's compounds. A significant percentage of all solid tumor patients display this perturbation, positioning them as potential candidates for treatment with the company's drug candidate. Learn more at: .
關於Alphina療法
Alphina Therapeutics是一家生物技術公司,正在開發一流的nAMPT小分子抑制劑,用於治療各種實體瘤。該公司由世界一流的科學家創立,並得到由風險投資家組成的強大投資者集團的支持,該公司還在開發一種專有檢測方法,以選擇腫瘤具有特定擾動的患者,這種擾動使他們的腫瘤對Alphina的化合物極其敏感。所有實體瘤患者中有很大一部分表現出這種不安,這使他們成爲使用該公司候選藥物進行治療的潛在候選人。在以下網址了解更多:.
Contacts:
Alphina Therapeutics
Nick Galli, CEO
+1 475 655 0541
[email protected]
聯繫人:
Alphina 療法
首席執行官尼克·加利
+1 475 655 0541
[電子郵件保護]
Vida Strategic Partners (on behalf of Alphina Therapeutics)
Tim Brons
+1 646 319 8981
[email protected]
維達戰略合作伙伴(代表 Alphina Therapeutics)
蒂姆·布朗斯
+1 646 319 8981
[電子郵件保護]
SOURCE Alphina Therapeutics
來源 Alphina Therapeut